Skip to main content
TipRanks
Go Ultimate75% OFF

Zhongzhi Pharmaceutical Holdings Limited (3737) Stock Price & Analysis

0 Followers

3737 Stock Chart & Stats

HK$0.66HK$0.00(0.00%)
At close: 4:00 PM GMT+8
HK$0.6HK$0.65HK$0.7HK$0.75Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
HKD 0.63 - HKD 0.66
52-Week Range
HKD 0.50 - HKD 0.98
Previous Close
HKD 0.66
Volume
N/A
Average Volume (3M)
375.90K
Market Cap
HKD 554.78M
Enterprise Value
HKD 588.70M
Total Cash (Recent Filing)
HKD 185.38M
Total Debt (Recent Filing)
HKD 87.63M
Price to Earnings (P/E)
26.1
Beta
0.06
Next Earnings
Mar 25, 2027 (Est.)
EPS Estimate
N/A
Dividend Yield
7.63%

Bulls Say, Bears Say

Bulls Say

Conservative Balance Sheet

Debt-to-equity around 0.21 and equity of roughly HK$1.0–1.1B indicate a conservative capital structure. This reduces financing strain and preserves flexibility to support operations or strategic investment through a weaker earnings period, improving resilience over the next several quarters.

Healthy Gross Margin

Gross margin remained about 54% in 2025 despite the downturn. That comparatively strong product-level profitability suggests the portfolio retains underlying economic value and gives management a base from which to rebuild operating profit if revenue stabilizes and costs are controlled.

Positive Cash Generation

Operating cash flow remained positive and free cash flow was about HK$69.9M in 2025, showing the business still converts activity into cash. This supports ongoing funding needs and reduces reliance on external financing, even though the cash result weakened year over year.

Bears Say

Revenue Contraction

Revenue declined sharply in 2025 after modest growth in 2024, while reported revenue growth was -15.17%. A sustained top-line contraction would weaken scale benefits, reduce funds available for investment, and make recovery dependent on renewed demand across the company's medicine and healthcare channels.

Severe Margin Compression

Net margin compressed to about 1.0% from 4.3% and operating margin fell to roughly 3.2%, leaving a much thinner earnings cushion. This reduces resilience to cost pressure, limits internal reinvestment capacity, and makes profits more sensitive to even modest operating setbacks.

Declining Free Cash Flow

Although free cash flow remained positive, its approximately 48% year-over-year decline highlights weaker cash conversion or greater cash investment needs. Continued volatility could constrain funding for growth, dividends, or operations and diminish the protection provided by current cash generation.

Zhongzhi Pharmaceutical Holdings Limited News

3737 FAQ

What was Zhongzhi Pharmaceutical Holdings Limited’s price range in the past 12 months?
Zhongzhi Pharmaceutical Holdings Limited lowest stock price was HK$0.50 and its highest was HK$0.98 in the past 12 months.
What is Zhongzhi Pharmaceutical Holdings Limited’s market cap?
Zhongzhi Pharmaceutical Holdings Limited’s market cap is HK$554.78M.
When is Zhongzhi Pharmaceutical Holdings Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Zhongzhi Pharmaceutical Holdings Limited’s earnings last quarter?
Zhongzhi Pharmaceutical Holdings Limited released its earnings results on Aug 26, 2026. The company reported HK$0.012 earnings per share for the quarter.
Is Zhongzhi Pharmaceutical Holdings Limited overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Zhongzhi Pharmaceutical Holdings Limited pay dividends?
Zhongzhi Pharmaceutical Holdings Limited pays an annual dividend of HK$0.05 which represents an annual dividend yield of 7.63%. See more information on Zhongzhi Pharmaceutical Holdings Limited dividends here
What is Zhongzhi Pharmaceutical Holdings Limited’s EPS estimate?
Zhongzhi Pharmaceutical Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zhongzhi Pharmaceutical Holdings Limited have?
Zhongzhi Pharmaceutical Holdings Limited has 863,600,000 shares outstanding.
What happened to Zhongzhi Pharmaceutical Holdings Limited’s price movement after its last earnings report?
Zhongzhi Pharmaceutical Holdings Limited reported an EPS of HK$0.012 in its last earnings report. Following the earnings report the stock price went down -3.623%.
Which hedge fund is a major shareholder of Zhongzhi Pharmaceutical Holdings Limited?
Currently, no hedge funds are holding shares in HK:3737
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology